Talnetant (SB-223412) is a neurokinin 3 receptor antagonist developed by GlaxoSmithKline which is being researched for several different functions primarily for irritable bowel syndrome however its use as a potential antipsychotic drug for the treatment of schizophrenia has been discontinued.
This page contains content from the copyrighted Wikipedia article "Talnetant"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
